Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.32 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890119 | 0.93 | DDB1 (0.37) | DDB1CRBNMAOAMAOBNCOA1 | |
| SCHEMBL9890447 | 0.92 | DDB1 (0.34) | DDB1CRBNNCOA1NPC1MAPT | |
| SCHEMBL9890379 | 0.92 | DDB1 (0.36) | DDB1CRBNMAOAMAOBNCOA1 | |
| SCHEMBL9890570 | 0.90 | CDK4 (0.33) | DDB1CRBNNPC1MAPTKDM4E | |
| SCHEMBL9890575 | 0.89 | CDK4 (0.33) | DDB1CRBNNPC1MAPTKDM4E | |
| SCHEMBL9890197 | 0.89 | DDB1 (0.36) | DDB1CRBNMAOAMAOBNCOA1 | |
| SCHEMBL9890583 | 0.87 | NPC1 (0.36) | NCOA1NPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL9890590 | 0.86 | MAOA (0.33) | MAOAMAOBACHE | |
| SCHEMBL9890562 | 0.86 | MAPT (0.37) | NCOA1NPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL9890569 | 0.85 | MAOA (0.43) | DDB1CRBNMAOAMAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120138915-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120138915-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | DDB1 1454/4885CRBN 1944/4885MAOA 455/4885 |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | DDB1 1454/4885CRBN 1944/4885MAOA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.